Drugs / Isovue-M 200
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (10) | US (FDA) | ISOVUE-250 | — | 1986-09-10 – 2025-10-10 | fda.gov ↗ |
| Approved | US (FDA) | ISOVUE-250 | — | 1985-12-31 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03071328 | Jan 2018 → Mar 2021 | castration-resistant prostate carcinoma, renal cell carcinoma, urothelial carcinoma | Duke University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isovue-M 200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03071328 ↗ |
| Route | Other | “injected intra-tumorally under CT fluoroscopy guidance” NCT03071328 ↗ |